Stem Cell Transplant for Inborn Errors of Metabolism

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

January 31, 1995

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
AdrenoleukodystrophyMetachromatic LeukodystrophyGloboid Cell LeukodystrophyGaucher's DiseaseFucosidosisWolman DiseaseNiemann-Pick DiseaseBatten DiseaseGM1 GangliosidosisTay Sachs DiseaseSandhoff Disease
Interventions
PROCEDURE

Stem Cell Transplant

The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).

DRUG

Busulfan, Cyclophosphamide, Antithymocyte Globulin

"Subjects will receive BUSULFAN intravenously (IV)- patients \< or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients \> 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism | Biotech Hunter | Biotech Hunter